Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
Wassmann B, Gökbuget N, Scheuring UJ, Binckebanck A, Reutzel R, Gschaidmeier H, Hoelzer D, Ottmann OG; GMALL Study Group. Wassmann B, et al. Among authors: scheuring uj. Ann Hematol. 2003 Nov;82(11):716-20. doi: 10.1007/s00277-003-0728-8. Epub 2003 Aug 28. Ann Hematol. 2003. PMID: 14648032 Clinical Trial. No abstract available.
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Atta J, Petershofen EK, Gehrke B, Gschaidmeier H, Hoelzer D, Ottmann OG. Scheuring UJ, et al. Blood. 2003 Jan 1;101(1):85-90. doi: 10.1182/blood-2002-02-0360. Epub 2002 Aug 22. Blood. 2003. PMID: 12393581 Free article. Clinical Trial.
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gökbuget N, Atta J, Brück P, Rieder H, Schoch C, Leimer L, Schwerdtfeger R, Ehninger G, Lipp T, Perz J, Stelljes M, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: scheuring uj. Blood. 2004 Feb 15;103(4):1495-8. doi: 10.1182/blood-2003-01-0154. Epub 2003 Oct 23. Blood. 2004. PMID: 14576058 Free article. Clinical Trial.
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B, Pfeifer H, Stadler M, Bornhaüser M, Bug G, Scheuring UJ, Brück P, Stelljes M, Schwerdtfeger R, Basara N, Perz J, Bunjes D, Ledderose G, Mahlberg R, Binckebanck A, Gschaidmeier H, Hoelzer D, Ottmann OG. Wassmann B, et al. Among authors: scheuring uj. Blood. 2005 Jul 15;106(2):458-63. doi: 10.1182/blood-2004-05-1746. Epub 2005 Apr 7. Blood. 2005. PMID: 15817679 Free article. Clinical Trial.
33 results